• 1
    Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, Suppes T, Keck Jr PE, McElroy S, Grunze H, Mintz J, Post RM. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psych Scand 2007;115:360365.
  • 2
    Shea S, Bigger JT Jr, Campion J et al. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST). Control Clin Trials 1992;13:466486.
  • 3
    Charlson ME, Horwitz RI. Applying results of randomised trials to clinical practice: impact of losses before randomisation. BMJ (Clin Res Ed) 1984;289:12811284.
  • 4
    Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:10791087.
  • 5
    AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;383:21052115.
  • 6
    Rendell JM, Juszczak E, Hainsworth J et al. Developing the BALANCE trial – the role of the pilot study and start-up phase. Bipolar Disord 2004;6:2631.
  • 7
    Hotopf M, Lewis G, Normand C. Putting trials on trial–the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health 1997;51:354358.
  • 8
    Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:11811184.
  • 9
    Rendell JM, Geddes JR. Barriers to recruitment to RCTs: a Delphi study. Fifth European Stanley Conference on Bipolar Disorder. October 5th–7th 2006 Abstract 1–050 in abstract book (Oral presentation and poster).
  • 10
    Geddes JR. Generating evidence to inform policy and practice: the example of the second generation ‘‘atypical’’ antipsychotics. Schizophr Bull 2003;29:105114.
  • 11
    The National Institute of Clinical Excellence (NICE). Accessed online
  • 12
    American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, revision. Am J Psychiatry 2002;159(suppl.):150.
  • 13
    Licht RW, Gouliaev G, Vestergaard P, Frydenberg M. Generalisability of results from randomised drug trials. A trial on antimanic treatment. Br J Psychiatry 1997;170:264267.
  • 14
    Rendell JM, Merritt RM, Geddes JR. Incentives and disincentives to participation by clinicians in randomised controlled trials. The Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: MR000021.
  • 15
    Licht RW. Prophylaxis in bipolar disorder: methodological implications of an almost completed lamotrigine-vs-lithium study. 15th European Congress of Psychiatry, March 17–21 2007. Eur Psychiatry 2007;22:S50 (Abstract).